OBJECTIVES: To determine whether there is differential response to placebo or citalopram among older patients with and without deficient response inhibition (DRI). DESIGN: This is an 8-week, double-blind, placebo-controlled trial. SETTING: Outpatient psychiatry. PARTICIPANTS: Unipolar depressed patients aged 75 years and older. INTERVENTION: Citalopram (20-40 mg/day) or placebo pill. MEASUREMENTS: Baseline Stroop Color-Word Test and weekly 24-item Hamilton Rating Scale for Depression assessments. RESULTS:Citalopram-treated patients with DRI did significantly worse than placebo-treated patients with DRI. Conversely, citalopram-treated patients without DRI did significantly better than placebo-treated patients without DRI. CONCLUSION:Patients with late-life depression and DRI respond worse to selective serotonin reuptake inhibitor (SSRI) thanplacebo. These findings suggest that there may be a deleterious interaction between DRI and antidepressant medication in late-life depression and that the mechanism of SSRI and placebo response is different.
RCT Entities:
OBJECTIVES: To determine whether there is differential response to placebo or citalopram among older patients with and without deficient response inhibition (DRI). DESIGN: This is an 8-week, double-blind, placebo-controlled trial. SETTING:Outpatient psychiatry. PARTICIPANTS: Unipolar depressedpatients aged 75 years and older. INTERVENTION: Citalopram (20-40 mg/day) or placebo pill. MEASUREMENTS: Baseline Stroop Color-Word Test and weekly 24-item Hamilton Rating Scale for Depression assessments. RESULTS:Citalopram-treated patients with DRI did significantly worse than placebo-treated patients with DRI. Conversely, citalopram-treated patients without DRI did significantly better than placebo-treated patients without DRI. CONCLUSION:Patients with late-life depression and DRI respond worse to selective serotonin reuptake inhibitor (SSRI) than placebo. These findings suggest that there may be a deleterious interaction between DRI and antidepressant medication in late-life depression and that the mechanism of SSRI and placebo response is different.
Authors: Kirk I Erickson; Michael P Milham; Stanley J Colcombe; Arthur F Kramer; Marie T Banich; Andrew Webb; Neal J Cohen Journal: Hum Brain Mapp Date: 2004-02 Impact factor: 5.038
Authors: Ben J Harrison; Marnie Shaw; Murat Yücel; Rosemary Purcell; Warrick J Brewer; Stephen C Strother; Gary F Egan; James S Olver; Pradeep J Nathan; Christos Pantelis Journal: Neuroimage Date: 2005-01-01 Impact factor: 6.556
Authors: Helen S Mayberg; J Arturo Silva; Steven K Brannan; Janet L Tekell; Roderick K Mahurin; Scott McGinnis; Paul A Jerabek Journal: Am J Psychiatry Date: 2002-05 Impact factor: 18.112
Authors: Monique A Pimontel; David Rindskopf; Bret R Rutherford; Patrick J Brown; Steven P Roose; Joel R Sneed Journal: Am J Geriatr Psychiatry Date: 2015-05-21 Impact factor: 4.105
Authors: Eric J Lenze; Tamara Hershey; John W Newcomer; Jordan F Karp; Daniel Blumberger; Jennifer Anger; Peter Doré; David Dixon Journal: Int J Geriatr Psychiatry Date: 2014-03-14 Impact factor: 3.485
Authors: Sarah Shizuko Morimoto; Faith M Gunning; Dora Kanellopoulos; Christopher F Murphy; Sibel A Klimstra; Robert E Kelly; George S Alexopoulos Journal: Int J Geriatr Psychiatry Date: 2011-05-25 Impact factor: 3.485
Authors: Katie L Bessette; Aimee J Karstens; Natania A Crane; Amy T Peters; Jonathan P Stange; Kathleen H Elverman; Sarah Shizuko Morimoto; Sara L Weisenbach; Scott A Langenecker Journal: Neuropsychol Rev Date: 2020-01-15 Impact factor: 7.444
Authors: George S Alexopoulos; Patrick J Raue; Dimitris N Kiosses; R Scott Mackin; Dora Kanellopoulos; Charles McCulloch; Patricia A Areán Journal: Arch Gen Psychiatry Date: 2011-01
Authors: Joseph S Goveas; Mark A Espeland; Patricia E Hogan; Hilary A Tindle; Regina A Shih; Jane M Kotchen; Jennifer G Robinson; Deborah E Barnes; Susan M Resnick Journal: J Geriatr Psychiatry Neurol Date: 2014-02-28 Impact factor: 2.680